BIOTECH FRACTIONAL CFO

Strategic CFO Support for Scaling Biotech Companies

Boston-based fractional and interim CFO for early-stage biotech companies in the US and Europe. I put in the systems, processes, controls and team, then take you through financings and transactions to closing.

Transactions closed as CFO: Euronext RTO · $87M sale to Calliditas · $135M Nasdaq SPAC

Alex Grassin, fractional CFO for biotech

CFO roles & engagements

Genkyotex logo
Aleva Neurotherapeutics logo
HiFiBiO Therapeutics logo
Enodia Therapeutics logo
enGene logo

Enodia and enGene engagements delivered through Danforth Advisors

Earlier finance roles

Novartis logo
Alexion logo

I specialize in

Finance Function Build-Out

I build the finance function from the ground up: accounting, systems, processes, controls and the team to run them, audit-ready under US GAAP or IFRS.

Planning, Runway & Board Reporting

I give founders and boards the numbers they need to decide: business plans, cash runway and use-of-proceeds models, and board and investor reporting.

Financings & Transactions to Closing

I take financings and transactions through to closing: data room, diligence, cap table and closing mechanics, for private rounds, IPO readiness, RTO/SPAC listings and M&A.

Governance, Legal & Cross-Border

I keep the company structurally sound and investor-ready across the US and Europe: entities, intercompany and tax structure, equity plans and insurance.

Operations & Restructuring

I run the functions outside R&D, including HR, benefits, IT and facilities, and lead cost-reduction programs when runway demands it.

Interim CFO & Transitions

I usually come in as a company’s first CFO on an interim basis to put the foundations in place. I also step in between permanent hires or during a leave, then hand over cleanly.

I specialize in

Finance Function Build-Out

I build the finance function from the ground up: accounting, systems, processes, controls and the team to run them, audit-ready under US GAAP or IFRS.

Planning, Runway & Board Reporting

I give founders and boards the numbers they need to decide: business plans, cash runway and use-of-proceeds models, and board and investor reporting.

Financings & Transactions to Closing

I take financings and transactions through to closing: data room, diligence, cap table and closing mechanics, for private rounds, IPO readiness, RTO/SPAC listings and M&A.

Governance, Legal & Cross-Border

I keep the company structurally sound and investor-ready across the US and Europe: entities, intercompany and tax structure, equity plans and insurance.

Operations & Restructuring

I run the functions outside R&D, including HR, benefits, IT and facilities, and lead cost-reduction programs when runway demands it.

Interim CFO & Transitions

I usually come in as a company’s first CFO on an interim basis to put the foundations in place. I also step in between permanent hires or during a leave, then hand over cleanly.

Alex Grassin, fractional CFO for biotech

BIOTECH FRACTIONAL CFO

I build the finance function biotech companies need to scale

I'm a CFO with 25 years in finance across the US and Europe. I trained in audit at KPMG Paris and held finance roles at Alexion and Novartis before moving into biotech leadership.


As CFO of Genkyotex in Geneva (2012–2021), I led finance and every function outside R&D for nine years. I closed the company's private financings, executed its reverse takeover onto Euronext, served as public-company CFO for four years, and led the closing of its $87M sale to Calliditas through to delisting.


Since 2022, through Grassin Consulting, I've been fractional and interim CFO to biotech companies including HiFiBiO Therapeutics, Enodia Therapeutics and enGene: building finance functions, restructuring cost bases, and supporting financings and transactions.

Selected closings

Transactions I worked on as CFO, through to closing.

Euronext Paris & Brussels

Reverse takeover

Reverse takeover

Reverse takeover

Genkyotex’s stock-market listing through a reverse merger with Genticel.

CFO, Genkyotex · Ran the closing

Sale to Calliditas Therapeutics

$87M

$87M

$87M

Sale of Genkyotex, followed by the tender offer and delisting.

CFO, Genkyotex · Ran the closing

Nasdaq SPAC combination

$135M

$135M

$135M

enGene’s business combination with Forbion European Acquisition Corp.

Interim CFO, enGene, during the transaction

25

Years in finance

25

Years in finance

25

Years in finance

6

Countries, US & Europe

6

Countries, US & Europe

6

Countries, US & Europe

$300M

Financings & transactions supported

$300M

Financings & transactions supported

$300M

Financings & transactions supported

3

Major transactions: RTO, SPAC, M&A

3

Major transactions: RTO, SPAC, M&A

3

Major transactions: RTO, SPAC, M&A

FAQ

Didn't find the question you were looking for?

What is a Fractional CFO?

Why hire a Fractional CFO instead of a full-time CFO?

What services do you provide?

What types of companies do you work with?

How do you typically engage with clients?

Do you help with fundraising?

What is your experience?

How quickly can you start?

How is your work different from an accountant or bookkeeper?

How do we get started?

BIOTECH FRACTIONAL CFO

Let's get in touch

Need fractional CFO support or have questions?

I’m here to help you.

BIOTECH FRACTIONAL CFO

Let's get in touch

Need fractional CFO support or have questions?

I’m here to help you.

BIOTECH FRACTIONAL CFO

Let's get in touch

Need fractional CFO support or have questions?

I’m here to help you.